US FDA’s Genetic Metabolic Diseases Adcomm Debuts With Zevra’s Arimoclomol

Stage
The Genetic Metabolic Diseases Adcomm is scheduled for its first meeting on 2 August, although the committee's standing members have not yet been announced. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers